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Abstract 
Aims: To investigate the associated risk of stroke after discharge of infective endocarditis (IE) in patients 
with stroke during IE admission compared with patients without stroke during IE admission. 
Methods and Results: Using Danish nationwide registries we identified non-surgically treated patients with 
IE discharged alive, in the period from 1996-2016. The study population was grouped in 1) patients with 
stroke during IE admission and 2) patients without stroke during IE admission. Multivariable adjusted Cox 
proportional hazard analysis was used to compare the associated risk of stroke between groups. 
We identified 4,284 patients with IE, of whom 239 (5.6%) had a stroke during IE admission. We identified 
differentials in the associated risk of stroke during follow-up between groups (p=0.006 for interaction with 
time). The associated risk of stroke was higher in patients with stroke during IE admission with a one year 
follow-up, HR=3.21 (95% CI: 1.66-6.20) compared with patients without stroke during IE admission. From 
one to five years of follow-up, we identified no difference in the associated risk of stroke between groups, 
HR=0.91 (95% CI: 0.33-2.50). 
Conclusion: Patients with non-surgically treated IE with a stroke during IE admission were at significant 
higher associated risk of subsequent stroke within the first year of follow-up as compared with patients 
without a stroke during IE admission. This risk difference was not evident beyond one year of discharge. 
These findings underline the need for identification of causes and mechanisms of recurrent strokes after IE to 
develop preventive means.  
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Introduction 
Stroke is a common and disabling complication in patients with infective endocarditis (IE) and 
contributes to the high mortality.
1–5
 Much attention has been focused on the risk and prevention of 
stroke in the initial phase of IE.
5–8
 Thus, little data are available on the long-term risk of recurrent 
stroke in patients having a cerebral embolic event during IE admission. 
9–11
 An American, 
population-based study with a case crossover design observed an increased risk of stroke up to five 
months after the diagnosis of IE.
12
 Further, a Taiwanese population-based study identified that 
patients surviving IE were at a higher associated risk of stroke compared with controls from the 
background population.
13
 However, no study has yet assessed the associated risk of stroke in 
patients with and without stroke during IE admission treated with medical therapy only. Such data 
should address the potential magnitude of differences in risk between subgroups of patients with IE 
and may help guide clinical follow-up of medically treated IE patients. Further, these data may be 
of importance  for the development of future strategies for preventive regimens, which previously 
has been shown to be difficult.
14
 The objective of this study was to investigate the long-term 
associated risk and timing of stroke in patients with and without stroke during IE admission.  
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Methods 
Data sources 
Every Danish citizen is provided with a unique identifier making it possible to crosslink different nationwide 
administrative registries. We used the Danish National Patient Registry, the Danish Prescription Registry, 
and the Cause of Death Registry. 
The Danish National Patient Registry was initiated in 1977 and provides information on every patient 
admitted to a Danish Hospital based in the discharge paper filled by the discharging physician. Diagnoses 
codes is stated in the discharge paper based on the International Classification of Diseases (ICD)-10 from 
1994 and the ICD-8 before 1994. Further, surgical procedures were added to the National Patient Registry 
from 1996 and medical examinations from 2000 where the coding is based upon the Nordic Medico-
Statistical Committee Classification of Surgical Procedures. The National Patient Registry was used to 
identify the study population, the main outcome, and baseline characteristics. 
The Danish Prescription Registry holds information on every prescription filled from a Danish pharmacy 
from 1994 based upon the Anatomical Therapeutic Chemical Classification System (ATC codes). The 
registry provides information on type of drug prescribed, strength of drug, package size, and date of filling.  
The Danish Prescription Registry was used to identify concomitant pharmacotherapy at baseline defined as 
filled prescription six months prior to IE admission. The Cause of Death Registry provides information on 
date of death and cause of death based on ICD-10 codes.
15
 
The Danish registries are of high quality and has been described in detail previously.
16,17
 
Study population, outcome, and follow-up 
The study population was derived from the Danish National Patient Registry and included patients with first 
time hospitalization due to IE according to the following ICD-10 codes: I33, I38, and I39.8 in the period 
from 1996-2016 using primary and secondary diagnosis codes. Patients with these codes and a length of 
hospital stay ≥14 days have been validated with a positive predictive value of 90% in the National Patient 
Registry. Patients coded as IE with a length of hospital stay <14 days were excluded.
18,19
 Further, patients 
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undergoing cardiac surgical treatment during IE admission were excluded due to the risk of stroke 
subsequent and during surgery for heart valve replacement.
20
 Patients not discharged alive were excluded. 
Patients with a stroke or transient cerebral ischemia (TCI) any time prior to IE admission were excluded. The 
study population was grouped in 1) patients with stroke during IE admission, and 2) patients without stroke 
during IE-admission. Hospital admission for IE was identified as the combined hospitalization in which a 
diagnosis of IE was given. In that way, we accounted for transfers between departments and hospitals during 
the course of IE. If a primary or secondary diagnosis code of stroke (ICD-10 codes: DI61-DI64) were given 
during this hospitalization the patient was categorized as ‘stroke during IE admission’. Figure 1 shows a flow 
chart of the patient selection process. The primary outcome was defined as an inpatient, primary diagnosis of 
stroke, including ischemic, intracerebral hemorrhage and non-classified stroke (see Supplemental Table 1 for 
specific codes). The codes of the primary outcome have been validated in the Danish National Patient 
Registry with a positive predictive value between 74% and 97%.
21
 Diagnosis codes of unspecified stroke 
from the Danish National Patient Registry has been identified, in a validation study, to account for ischemic 
stroke in  57.1%-63.8% of the cases. Our secondary outcome was all-cause mortality. The patients were 
followed from date of discharge after IE until: hospital admission for stroke, death, emigration, end of study 
period (December 31, 2016), or a maximum of five years of follow-up.  
Statistics 
Baseline characteristics were shown by study groups (patients with and without stroke during IE admission). 
Categorical variables were shown in the counts and percentages while continuous variables were shown with 
a median and 25 and 75 percentiles. The Chi-square test was used to assess differences in baseline 
characteristics between groups for categorical variables and the Kruskal-Wallis test was used for continuous 
variables. Crude incidence rates of stroke were presented for the two groups per 1,000 person years (PY) and 
with a 95% confidence interval (CI). Cumulative incidence curves for time to stroke were plotted for the two 
study populations using the Aalen-Johansen estimator accounting for death as competing risk. Gray’s test 
was used to identify difference between curves. Mortality rate for the two groups were plotted using Kaplan-
Meier estimates and the log-rank test for difference between curves.  
Multivariable adjusted Cox proportional hazard analysis was used to examine the associated risk of stroke 
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between the two groups and to identify factors at baseline and their associated risk of stroke. The following 
covariates were included in the model: stroke during IE admission, sex, age, calendar year, heart failure 
before IE admission, chronic obstructive lung disorder, pacemaker before IE admission, aortic valve disease, 
mitral valve disease, renal disease and dialysis before IE admission, heart valve surgery, antihypertensive 
drugs, corticosteroid treatment, atrial fibrillation, anticoagulant therapy (vitamin K-antagonist, dabigatran, 
rivaroxaban, or apixaban), glucose lowering treatment, antiplatelet therapy (clopidogrel and aspirin). The 
proportional hazard assumption was tested for the primary outcome (stroke) and death, and we identified a p-
value of 0.006 and 0.006 for interaction with follow-up time for the primary outcome and all-cause mortality, 
respectively. Therefore, follow-up time was split at one year of follow-up. We tested whether there was an 
interaction with sex and age on the primary outcome. Further, linearity for age and hospital duration was 
tested. Results were presented with a hazard ratio (HR) and a 95% CI. A p-value less than 0.05 was 
considered statistically significant. We performed a sensitivity analysis including patients with a TCI or 
stroke during IE admission or in a period of six months prior to IE admission in the group defined as ‘stroke 
during IE admission’. Further, we conducted five additional sensitivity analyses: 1) we included patients 
undergoing heart valve surgery during IE admission, 2) we split follow-up time at 0-90 days of follow-up, 
and 90 days and up to five years of follow-up, 3) we investigated the associated risk of stroke in patients with 
stroke during IE admission compared with patients without stroke during IE admission with a mechanical 
prosthetic heart valve and without a mechanical prosthetic heart valve, 4) we investigated the associated risk 
of stroke in patients with prior myocardial infarction and treated with aspirin, 5) we investigated the risk of 
stroke in patients treated with antithrombotic and/or anticoagulant therapy compared with patients with 
stroke during IE admission. 
All statistical analyses were performed using the SAS statistical software, version 9.4 (SAS Institute, Inc., 
Cary, NC, USA). 
Funding 
No extramural funding was used to support this work. The authors are solely responsible for the design and 
conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. 
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Results 
We included a total of 4,284 patients with IE, 239 (5.6%) patients with stroke and 4,045 (94.4%) patients 
without stroke during IE admission. For patients with stroke during IE admission, 140 (58.6%) had an 
ischemic lesion, 23 (9.8%) had a hemorrhagic lesion, and 76 (33.0%) were categorized as having a stroke 
without further specifications. Further, for patients with stroke during IE admission, 136 (56.9%) were 
admitted with IE at the same date as admission for stroke while 103 patients (43.1%) had a diagnosis of 
stroke within hospitalization for IE. had the Table 1 presents characteristics for the two study populations. 
Patients with stroke during IE admission were older, more often female, and had a longer length of stay in 
hospital. We identified no difference in anticoagulant therapy or antiplatelet therapy six months prior to IE 
admission between groups, see Table 1. 
Incidence of stroke subsequent to IE discharge 
For patients with stroke during IE admission, 15 patients were hospitalized with stroke during follow-up, 3 
patients (20.0%) with hemorrhagic stroke, 6 patients (40.0%) with ischemic stroke, and 6 patients (40.0%) 
with unspecified stroke, see Supplemental Table 2. The median time from hospital discharge to event was 74 
days (25 and 75 percentiles 21-581 days). For patients without stroke during IE admission, 145 patients were 
hospitalized with stroke during follow-up, 30 patients (20.7%) with hemorrhagic stroke, 74 (51.0%) with 
ischemic stroke, and 41 (28.3%) with unspecified stroke. 
The crude incidence rate of stroke within one year of follow-up was 62.2 cases / 1,000 PY (95% CI: 34.4-
112.3) and 17.2 cases / 1,000 PY (95% CI 13.3-22.2) for patients with and without stroke during IE 
admission, respectively. From one year after discharge and up to five years after discharge, the incidence rate 
of stroke was 7.0 cases of stroke / 1,000 PY (95% CI: 2.6-18.6) and 7.3 / 1,000 PY (95% CI: 5.9-9.1) for 
patients with and without stroke during IE admission, respectively. Figure 2 panel A and B show the 
cumulative incidence of stroke for the two study groups with one year of follow-up (p<0.0001 for difference 
between curves) and from one to five years of follow-up (p=0.86 for difference between curves). Within the 
first six months after IE discharge, we observed that 21.0% and 24.3% filled a prescription for an 
anticoagulant drug (p=0.24 for difference between groups), 32.6% and 29.2% filled a prescription for aspirin 
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(p=0.25), and 16.7% and 4.1% filled a prescription for clopidogrel (p<0.0001) for patients with and without 
a stroke during IE, respectively. Among patients with stroke during IE admission, 18 patients (7.5%) 
underwent valve surgery during follow-up with a median time to surgery from IE discharge of 257 days (25 
and 75 percentiles: 89-824 days). Among patients without stroke during IE admission, 395 patients (9.8%) 
underwent valve surgery during follow-up with a median time to surgery from IE discharge of 313 days (25 
and 75 percentiles: 90-1,310 days). 
Associated risk of stroke between study groups 
In a multivariable adjusted analysis, at one year of follow-up, we identified a higher associated risk of 
subsequent stroke in patients with stroke during IE admission compared with patients without a stroke, 
HR=3.21 (95% CI: 1.66-6.20). With one to five years of follow-up, we found no significant difference in the 
associated risk of stroke in patients with stroke during IE admission compared with patients without a stroke, 
HR=0.91 (95% CI: 0.33-2.50) in a multivariable adjusted analysis. Age or sex did not modify the associated 
risk of stroke. Figure 3 shows factors associated with stroke with up to one year of follow-up and one to five 
years of follow-up, panel A and panel B, respectively. With up to one year of follow-up no other factors than 
stroke during IE admission were associated with an increased risk of subsequent stroke. With one to five 
years of follow-up, we identified that age was associated with an increased risk of stroke subsequent to IE 
discharge. 
Mortality 
The all-cause mortality rate for the two study groups are shown in Figure 2 panel C and D. One-year 
mortality rate was 23.1% and 17.7% (p=0.01 for difference between curves) for patients with and without a 
stroke during IE admission, respectively. In an adjusted analysis, the mortality rate remained statistically 
significant higher in patients with a stroke during IE admission compared with patients without a stroke 
during IE admission, HR=1.37 (95% CI: 1.03-1.82). With one to five years of follow-up, the mortality rate 
was 35.2% and 31.0% (p=0.18 for difference between curves) for patients with and without a stroke during 
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IE admission, respectively. In an adjusted analysis, the difference in the mortality rate remained statistically 
non-significant between groups, HR=1.26 (95% CI: 0.94-1.69).  
Sensitivity analyses 
We found no major differences from our primary findings when stroke six months prior to IE admission was 
included and TCI also was included as an exposure: 250 patients were classified as patients with stroke 
during IE admission and 4034 patients were classified without stroke during IE admission. The one-year 
incidence of stroke was 58.6 / 1,000 PY (95% CI: 32.5-105.8) for patients with a stroke or TCI during IE 
admission and 17.2 / 1,000 PY (95% CI: 13.4-22.2) for patients without a stroke or TCI during IE admission.  
When including patients undergoing heart valve surgery during IE admission (total study population, 
n=5,735) with up to one year of follow-up, we found an incidence rate of 59.2 strokes / 1,000 PY (95% CI: 
37.3-94.0) and 16.5 / 1,000 PY (95% CI: 13.2-20.6) for patients with and without stroke during IE 
admission, respectively. With one to five years of follow-up we found an incidence rate of 7.7 / 1,000 PY 
(95% CI: 3.8-15.3) and 7.5 / 1,000 PY (95% CI: 6.3-8.9) for patients with and without stroke during IE 
admission, respectively. 
Follow-up period was changed to 0-90 days of follow-up and from 90 days of follow-up and up to five years. 
No overall change was seen in the main results, Supplemental Figure 1. We found that patients without 
stroke with a prosthetic mechanical heart valve was at similar associated risk of stroke compared with 
patients with stroke during IE admission, Supplemental Figure 2. Patients with stroke during IE admission 
were at increased associated risk of stroke compared with patients without stroke during IE admission who 
also had prior myocardial infarction treated with aspirin, Supplemental Figure 3. Finally, patients with stroke 
during IE admission were at increased associated risk of stroke compared with patients without stroke during 
IE admission treated with antithrombotic and/or anticoagulant therapy prior to IE admission, Supplemental 
Figure 4. 
Discussion 
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We investigated the long-term risk of stroke in patients discharged alive after IE treatment with medical 
therapy only. Our study yielded three major findings: 1) the associated risk of stroke within the first year 
after IE discharge was three times higher for patients with a stroke during IE admission compared with 
patients without a stroke during IE admission, 2) after one year of follow-up, the associated risk of stroke 
was similar between groups, and 3) the mortality rate was significantly higher among patients with stroke 
during IE admission compared with patients without stroke within the first year after IE discharge, however 
after one year of follow-up mortality rates were no longer significantly different. 
It is well-known from randomized controlled trials that a previous stroke or TCI is a risk factor for 
subsequent stroke
22,23
, however whether a stroke during IE admission is a risk factor for stroke on the long 
term is not clear. Our data suggest that patients with a stroke during IE admission are at a considerably 
higher risk within the first year post discharge compared with patients without a stroke during IE admission. 
Residual vegetation, vulnerable valve tissue, post-infection alterations in coagulation or thrombocyte 
function, other co-morbidities or general patient frailty may explain this increased risk.   
The long-term risk of stroke in patients surviving IE has previously been investigated.
12,13
 A nationwide, 
population-based study from Taiwan compared IE survivors (n=10,116) with controls from the background 
population (n=17,926) and identified a significant higher risk of ischemic and hemorrhagic stroke, HR=1.59 
(95% CI: 1.40-1.80 and HR=2.37 (95% CI: 1.90-2.96)), respectively.
13
 This study included IE patients 
treated surgically and the risk of stroke may be related to the post-surgical risk of stroke. Our data only 
included non-surgically treated IE patients. We chose this approach in order to examine the relationship as 
homogenously as possible, as patients with a valve prothesis have many other competing factors for stroke 
and also anticoagulation therapy. However, in a sensitivity analysis, including patients treated surgically 
during IE admission, did not alter our main findings. The proportion of patients undergoing surgical 
treatment during IE admission and the proportion of patients with a prosthetic heart valve diagnosed with IE 
identified from our cohort are in line with previous population-based studies from Spain and the United 
States.
24,25
 Further, an American population-based study identified an increased risk of stroke not only 
around the time of IE diagnosis but also four months prior to and five months after IE in a case cross-over 
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design.
12
 Our study adds valuable knowledge to current data showing an increased associated risk of 
subsequent stroke after IE discharge in patients with a stroke during IE admission compared with patients 
without a stroke during IE admission for the first year only. Compared with previous literature, our data 
suggest that all IE patients carry a higher risk of stroke compared with patients without stroke risk factors.
23
 
We present data that are unique as we were able to follow an unselected cohort with long-term follow-up.  
Whereas no prior studies have assessed the risk of stroke subsequent to IE in patients with and without stroke 
during IE admission, some studies have investigated the mortality rate among IE survivors. A study by 
Thuny et al. showed an excess mortality in patients surviving IE compared with expected survival.
26
 Further, 
a population-based Swedish study found an increased standardized mortality ratio in patients surviving IE, 
which remained increased with up to five years of follow-up.
27
 High clinical awareness of stroke is needed 
especially in the first year after discharge where the occurrence of stroke is substantially higher in patients 
with stroke during IE admission compared with patients without a stroke during IE admission. However, 
beyond one year after discharge, mortality and stroke rates become similar between groups according to our 
data. 
Several studies have investigated factors at IE admission and the associated risk of stroke during IE 
admission. Size and mobility of the vegetation, Staphylococcus aureus etiology and mitral valve IE are 
factors considered to be associated with an increased risk of stroke during IE admission
3,28–31
, however these 
studies have not been able to identify factors associated with long-term stroke risk. With follow-up from one 
to five years of follow-up we identified that age was associated with an increased risk of stroke after IE 
discharge. 
The use of anticoagulant in patients with IE is an area of much debate
32
 and the recommendations on 
anticoagulant or antiplatelet therapy in patients with IE from the European Society of Cardiology (ESC) and 
the American Heart Association (AHA) are based on few studies.
10,11
 The initiation of aspirin in patients with 
IE is not recommended.
14
 For patients already treated with anticoagulant therapy before the onset of IE data 
from observational studies are conflicting. Snygg-Martin et al. showed that warfarin treatment on IE 
admission were associated with a decreased risk of cerebrovascular complications and with no increase in 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
12 
 
hemorrhagic lesions.
33
 In patients with Staphylococcus aureus IE, a study by Tornos et al. identified an 
increased risk of death due to neurologic complications in patients on anticoagulant therapy, however 
Rasmussen et al. identified no increased risk of cerebral hemorrhage in patients with Staphylococcus aureus 
IE treated with anticoagulant therapy.
34
 The aim of our study was not to determine safety and effectiveness 
of anticoagulant therapy during IE admission. Future studies are needed on this subject to guide clinical 
decision on this area.  
Limitations 
Our study has several limitations which need to be addressed. First, we identified 239 patients (5.6%) with a 
stroke during IE admission. This number is low in comparison with previous studies on this area,
3,35
 however 
these studies have been conducted on cohorts from referral centers which may differ from a large unselected 
cohort as ours. Further, our study population consisted of patients surviving IE and patients only receiving 
antibacterial therapy as IE treatment (i.e. surgically treated patients were excluded). In addition, differences 
on the awareness cerebral lesions of magnetic resonance imaging (MRI) may have led to differences between 
study populations.
36
 Our study did not have information on MRI, which could have described the cerebral 
lesion in more detail. Second, we had no data on vegetation size, affected valve, or microbiological etiology. 
This could have helped characterize whether differences were seen on the risk of stroke by residual 
vegetation, affected valve or type of microbiological agent. Further, data on intravenous drug users and 
blood pressure readings were not accessible from the registries used . Third, our outcome of stroke is based 
on diagnosis codes and no clinical data have been available to confirm a new case of stroke. To account for 
this limitation we only included in-hospital codes with a primary diagnosis code of stroke. 
Conclusion 
Patients with a stroke during IE admission were at a significant higher risk of subsequent stroke within one 
year of follow-up compared with patients without stroke during IE admission. This risk difference was not 
evident beyond one year of discharge. These findings underline the need for identification of causes and 
mechanisms of recurrent strokes after IE to develop preventive means. 
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Figure legends 
Figure 1. Patient selection. 
The figure shows a flow chart of the patient selection. 
Figure 2. Cumulative incidence of stroke and mortality rate 
The figure shows the cumulative incidence of stroke at 0-1 years of follow-up (panel A) and 1-5 years of 
follow-up (panel B) for patients with and without stroke during endocarditis admission. Further, the 
mortality rate for patients with and without stroke during endocarditis admission are seen with 0-1 years of 
follow-up (panel C) and 1-5 years of follow-up (panel D). 
Figure 3. Factors associated with stroke 
The figure shows factors included in the multivariable adjusted regression analysis and the associated risk of 
stroke subsequent to discharge for infective endocarditis for 0-1 years of follow-up (left panel) and 1-5 years 
of follow-up (right panel). 
Supplemental Figure 1. Cumulative incidence of stroke with 0-90 days and 90 days to five years of 
follow-up 
Supplemental Figure 1. The figure shows the cumulative incidence of stroke in patients with (red line) and 
without stroke during IE admission (black line) from 0-90 days of follow-up (panel A) and from 90 days of 
follow-up up to five years of follow-up (panel B). 
In adjusted analyses we found that patients with stroke during IE admission were at increased associated risk 
of stroke, HR=6.99 (95% CI: 2.96-16.53). With 90 days of follow-up to five years of follow-up no difference 
between groups were observed, HR=1.04 (95% CI: 0.48-2.24). 
IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence interval. 
Supplemental Figure 2. Cumulative incidence of stroke in patients with mechanical prosthetic heart 
valve 
Supplemental Figure 2. The figure shows the cumulative incidence of stroke in patients with stroke during IE 
admission and without a prosthetic mechanical heart valve (green line), patients without stroke during IE 
admission with a mechanical prosthetic heart valve (red line), and patients without stroke during IE 
admission without a prosthetic mechanical heart valve (black line). With 0-1 years of follow-up, the 
associated risk of stroke was HR=2.74 (95% CI: 1.34-5.62) and HR=1.91 (95% CI: 0.51-7.11) for patients 
with stroke during IE admission and patients with a prosthetic heart valve compared with patients without 
stroke during IE admission. With 1-5 years of follow-up the estimates were HR=1.00 (95% CI: 0.36-2.76) 
and HR=1.05 (95% CI: 0.34-3.27), respectively. 
IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence interval. 
Supplemental Figure 3. Cumulative incidence of stroke in patients with prior myocardial infarction 
and treated with aspirin. 
Supplemental Figure 3. The figure shows the cumulative incidence of stroke in patients with stroke during IE 
admission (green line), without stroke during IE admission (black line), and patients without stroke during IE 
admission with a previous myocardial infarction and treated with aspirin (red line). With 0-1 years of follow-
up, the associated risk of stroke was HR=2.90 (95% CI: 1.46-5.78) and HR=0.70 (95% CI: 0.20-2.48) for 
patients with stroke during IE admission and patients without stroke during IE admission with a previous 
myocardial infarction (MI) treated with aspirin compared with patients without stroke during IE admission 
without previous MI. With 1-5 years of follow-up the estimates were HR=0.91 (95% CI: 0.39-2.11) and 
HR=0.96 (95% CI: 0.35-2.64), respectively. 
MI: myocardial infarction, IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence 
interval. 
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Supplemental Figure 4. Cumulative incidence of stroke in patients treated with antithrombotic and/or 
anticoagulant therapy. 
Supplemental Figure 4. The figure shows the cumulative incidence of stroke for patients with stroke during 
IE admission not treated with antithrombotic or anticoagulant therapy prior to IE admission (dark blue line) 
compared with patients without stroke during IE admission treated with antithrombotic and/or anticoagulant 
therapy prior to IE admission. We identified the following estimates for the associated risk of stroke 
subsequent to IE discharge with 0-1 years of follow-up HR=5.10 (95% CI: 2.38-10.91), HR=4.47 (95% CI: 
0.63-31.62), HR=1.91 (95% CI: 0.62-5.91), and HR=4.59 (95% CI: 0.46-46.08) for patients with stroke 
during IE admission, patients without stroke during IE admission treated with anticoagulant therapy (green 
line), patients without stroke during IE admission treated with antithrombotic therapy (red line), and patients 
without stroke during IE admission treated with antithrombotic and anticoagulant therapy (light blue) 
compared with patients without stroke during IE admission not treated with antithrombotic or anticoagulant 
therapy (black line), respectively. With 1-5 years of follow-up the estimates were HR=1.23 (95% CI: 0.38-
3.97), HR=0.71 (95% CI: 0.26-1.92), HR=1.52 (95% CI: 0.60-3.86), and HR=0.95 (95% CI: 0.25-3.61), 
respectively. 
OAC: oral anticoagulation, IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence 
interval. 
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Table 1. Baseline patient characteristics  
 Stroke during IE 
admission 
No stroke 
during IE 
admission 
p-value 
Demographics    
   Number 239 4,045  
   Male, n (%) 139 (58.2) 2,622 (64.8) 0.04 
   Age (years), median (IQR) 71.9 (61.1-81.0) 69.7 (56.1-78.8) 0.01 
   Duration of hospital admission, median days (IQR) 54.0 (42.0-79.0) 42.0 (31.0-51.0) <0.0001 
    
Medical history during IE admission    
   Heart failure, (%) 28 (11.7) 472 (11.7) 0.98 
   Cardiac implantable electronic device, n (%) 9 (3.8) 281 (7.0) 0.06 
   Renal disease, n (%) 25 (10.5) 382 (9.4) 0.60 
   Renal dialysis, n (%) 21 (8.8) 273 (6.8) 0.23 
    
Comorbidity, medical history prior to IE admission    
    
   Heart failure, n (%) 39 (16.3) 820 (20.3) 0.14 
   Atrial flutter/fibrillation, n (%) 41 (17.2) 861 (21.3) 0.13 
   COLD, n (%) 20 (8.4) 447 (11.1) 0.20 
   Cardiac implantable electronic device, n (%) 12 (5.0) 506 (12.5) 0.001 
   Aortic valve disease, n (%) 60 (25.1) 882 (21.8) 0.23 
      Aortic stenosis, n (%) 36 (15.1) 577 (14.3)  
      Aortic regurgitation, n (%) 9 (3.8) 147 (3.6)  
      Other or non-classified aortic valve disease, n (%) 15 (6.3) 158 (3.9)  
   Mitral valve disease, n (%) 20 (8.4) 337 (8.3) 0.98 
      Mitral regurgitation, n (%) 8 (3.4) 209 (5.2)  
      Mitral prolapse, n (%) 0 35 (0.9)  
      Mitral stenosis, n (%) 0 25 (0.6)  
      Other or non-classified mitral valve disease, n (%) 12 (5.0) 68 (1.7)  
   Renal disease, n (%) 14 (5.9) 398 (9.8) 0.04 
   Renal dialysis, n (%) 9 (3.8) 226 (5.6) 0.23 
   Cancer, n (%) 37 (15.5) 630 (15.6) 0.97 
   Prosthetic heart valve, n (%) 23 (9.6) 513 (12.7) 0.16 
    
Prehospital medication    
   Aspirin, n (%) 65 (27.2) 1,140 (28.2) 0.74 
   Clopidogrel, n (%) 4 (1.7) 145 (3.6) 0.12 
   Anticoagulant therapy, n (%) 51 (21.3) 882 (21.8) 0.87 
   Glucose lowering medication, n (%) 31 (13.0) 541 (13.4) 0.86 
   Corticosteroids, n (%) 21 (8.8) 440 (10.9) 0.31 
   Lipid lowering medication, n (%) 55 (23.0) 1,025 (25.3) 0.42 
   Antihypertensives*, n (%) 91 (38.1) 1,431 (35.4) 0.40 
IHD: ischemic heart disease, COLD: chronic obstructive lung disease. 
*Defined as at least two drugs of antihypertensive medication (see Supplemental Table 1) 
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Figure 1. Patient selection. 
 
The figure shows a flow chart of the patient selection. 
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Figure 2. Cumulative incidence of stroke and mortality rate 
 
The figure shows the cumulative incidence of stroke at 0-1 years of follow-up (panel A) and 1-5 years of 
follow-up (panel B) for patients with and without stroke during endocarditis admission. Further, the 
mortality rate for patients with and without stroke during endocarditis admission are seen with 0-1 years of 
follow-up (panel C) and 1-5 years of follow-up (panel D). 
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Figure 3. Factors associated with stroke 
 
The figure shows factors included in the multivariable adjusted regression analysis and the associated risk of 
stroke subsequent to discharge for infective endocarditis for 0-1 years of follow-up (left panel) and 1-5 years 
of follow-up (right panel). 
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Supplemental Figure 1. Cumulative incidence of stroke with 0-90 days and 90 days to five years of 
follow-up
Supplemental Figure 1. The figure shows the cumulative incidence of stroke in patients with (red line) and 
without stroke during IE admission (black line) from 0-90 days of follow-up (panel A) and from 90 days of 
follow-up up to five years of follow-up (panel B). 
In adjusted analyses we found that patients with stroke during IE admission were at increased associated risk 
of stroke, HR=6.99 (95% CI: 2.96-16.53). With 90 days of follow-up to five years of follow-up no difference 
between groups were observed, HR=1.04 (95% CI: 0.48-2.24). 
IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence interval. 
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Supplemental Figure 2. Cumulative incidence of stroke in patients with mechanical prosthetic heart 
valve 
 
Supplemental Figure 2. The figure shows the cumulative incidence of stroke in patients with stroke during IE 
admission and without a prosthetic mechanical heart valve (green line), patients without stroke during IE 
admission with a mechanical prosthetic heart valve (red line), and patients without stroke during IE 
admission without a prosthetic mechanical heart valve (black line). With 0-1 years of follow-up, the 
associated risk of stroke was HR=2.74 (95% CI: 1.34-5.62) and HR=1.91 (95% CI: 0.51-7.11) for patients 
with stroke during IE admission and patients with a prosthetic heart valve compared with patients without 
stroke during IE admission. With 1-5 years of follow-up the estimates were HR=1.00 (95% CI: 0.36-2.76) 
and HR=1.05 (95% CI: 0.34-3.27), respectively. 
IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence interval.  
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Supplemental Figure 3. Cumulative incidence of stroke in patients with myocardial infarction and 
aspirin. 
 
Supplemental Figure 3. The figure shows the cumulative incidence of stroke in patients with stroke during IE 
admission (green line), without stroke during IE admission (black line), and patients without stroke during IE 
admission with a previous myocardial infarction and treated with aspirin (red line). With 0-1 years of follow-
up, the associated risk of stroke was HR=2.90 (95% CI: 1.46-5.78) and HR=0.70 (95% CI: 0.20-2.48) for 
patients with stroke during IE admission and patients without stroke during IE admission with a previous 
myocardial infarction (MI) treated with aspirin compared with patients without stroke during IE admission 
without previous MI. With 1-5 years of follow-up the estimates were HR=0.91 (95% CI: 0.39-2.11) and 
HR=0.96 (95% CI: 0.35-2.64), respectively. 
MI: myocardial infarction, IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence 
interval. 
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Supplemental Figure 4. Cumulative incidence of stroke in patients treated with antithrombotic and/or 
anticoagulant therapy. 
 
Supplemental Figure 4. The figure shows the cumulative incidence of stroke for patients with stroke during 
IE admission not treated with antithrombotic or anticoagulant therapy prior to IE admission (dark blue line) 
compared with patients without stroke during IE admission treated with antithrombotic and/or anticoagulant 
therapy prior to IE admission. We identified the following estimates for the associated risk of stroke 
subsequent to IE discharge with 0-1 years of follow-up HR=5.10 (95% CI: 2.38-10.91), HR=4.47 (95% CI: 
0.63-31.62), HR=1.91 (95% CI: 0.62-5.91), and HR=4.59 (95% CI: 0.46-46.08) for patients with stroke 
during IE admission, patients without stroke during IE admission treated with anticoagulant therapy (green 
line), patients without stroke during IE admission treated with antithrombotic therapy (red line), and patients 
without stroke during IE admission treated with antithrombotic and anticoagulant therapy (light blue) 
compared with patients without stroke during IE admission not treated with antithrombotic or anticoagulant 
therapy (black line), respectively. With 1-5 years of follow-up the estimates were HR=1.23 (95% CI: 0.38-
3.97), HR=0.71 (95% CI: 0.26-1.92), HR=1.52 (95% CI: 0.60-3.86), and HR=0.95 (95% CI: 0.25-3.61), 
respectively. 
OAC: oral anticoagulation, IE: infective endocarditis, adm: admission, HR: hazard ratio, CI: confidence 
interval. 
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Supplemental Table 1: Codes 
Category  Codes 
   
Exposure and outcome   
Stroke  ICD-10: DI61-64 
Transient cerebral ischemia  ICD-10: DG45 
   
Study population   
Infective endocarditis  ICD-10: DI33, DI38, DI398; ICD8: 421 
   
Comorbidity   
Cancer  ICD10: DC00-DC97; ICD8: 140-209 
Renal disease  ICD10: DN03-04, DN17-19, DR34, DI12-13; ICD8: 582-
586, 588. 
Renal dialysis  ICD-10: Z992. 
BJFD0 (not used for renal dialysis before IE admission) and 
BJFD2 
Chronic obstructive lung 
disease 
 ICD10: DJ42, DJ44; ICD8: 490-492 
Heart failure  ICD10: DI42, DI50, DI110, DJ819; ICD8: 4270, 4271. 
Ischemic heart disease  ICD10: DI20-25; ICD8: 410-414. 
Gastritis  ICD-10: DK25-DK27, DK29, DK22.1, ICD-8: 531-534. 
Dementia  ICD-10: DG30, DG31.1-31.2, ICD-8: 290 
Prosthetic heart valve  KFKD, KFMD, KFGE, KFJF 
Pacemaker  BFCA0 and BFCB0 
Atrial flutter/fibrillation  ICD-10: DI48; ICD8: 4274. 
Aortic valve disease  ICD-10: DI35; ICD8: 395, 396 
Mitral valve disease  ICD-10: DI34 ICD8: 394, 396 
Rheumatic disease  ICD-10: M05-06, M32-34, M353; ICD8: 7100, 7101, 7104, 
7140, 7141, 7142, 7148, 725. 
   
Pharmacotherapy   
Beta blockade  ATC code: C07 
Lipid lowering medication  ATC code: C10 
Vitamin K-antagonist  ATC code: B01AA 
Corticosteroid medication  ATC code: H02 
Glucose lowering medication  ATC code: A10 
Dabigatran  ATC code: B01AE07 
Rivaroxaban  ATC code: B01AF01 
Apixaban  ATC code: B01AF02 
Clopidogrel  ATC code: B01AC04 
Aspirin  ATC codes: B01AC06, N02BA01 
Hypertension  ATC codes: C02A, C02B, C02C, C02DA, C02DB, C02DD, 
C02DG, C02L, C03A-B, C03D-E, C03X, C07A-D, C07F, 
C08 C08G, C09AA, C09BA, C09BB, C09CA, C09DA, 
C09DB, C09XA02, C09XA52. 
ICD: international classification of diseases, ATC: Anatomical Therapeutical Classification System, RAS: renin 
angiotensin system, AIDS: acquired immune deficiency syndrome. 
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Supplemental Table 2. Type of stroke during IE admission and type of stroke 
during follow-up 
  Type of stroke during IE admission  
  Hemorrhagic 
stroke, N 
Ischemic 
stroke, N 
Unspecified 
stroke, N 
 
T
y
p
e 
o
f 
st
ro
k
e 
d
u
ri
n
g
 
fo
ll
o
w
-u
p
 
Hemorrhagic 
stroke, N 
1 1 1 3 
Ischemic 
stroke, N 
0 4 2 6 
Unspecified 
stroke, N 
0 2 4 6 
  1 7 7 15 
Only primary diagnoses were used to assess hospitalization due to stroke after IE 
discharge. 
IE: infective endocarditis. 
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